Published on
Monday, January 10, 2011
Principal Deputy Commissioner
Joshua Sharfstein's unexpected exit from FDA has prompted Commissioner
Margaret Hamburg to launch a 60-day organizational review. Drug developers will
want to see whether Commissioner Hamburg is really going to tackle the hard
issues.
The review is intended in part
to redistribute Sharfstein's portfolio, unwind bureaucratic rivalries, and
eradicate the impression that the agency was operating with two heads,
according to senior FDA officials who would not speak for attribution.